Maja Raicevic
Mira Samardzic1,2
Ivan Soldatovic
Rade Vukovic- 1Department of Endocrinology, Institute for Children’s Diseases, Clinical Centre of Montenegro, Podgorica, Montenegro
- 2Faculty of Medicine, University of Montenegro, Podgorica, Montenegro
- 3Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- 4Department of Endocrinology, Mother and Child Health Care Institute of Serbia “Dr Vukan Cupic”, Belgrade, Serbia
- 5School of Medicine, University of Belgrade, Belgrade, Serbia
Significant and unexplained variations in type 1 diabetes (T1D) incidence through the years were observed all around the world. The update on this disorder’s incidence is crucial for adequate healthcare resource planning and monitoring of the disease. The aim of this study was to give an update on the current incidence of pediatric T1D in Montenegro and to analyze incidence changes over time and how the exposure to different factors might have affected it. This retrospective cohort study included a total of 582 patients younger than 15 years who were newly diagnosed with T1D during the past 30 years. The average age at diagnosis was 8.4 ± 3.91 years. The mean annual incidence of T1D in the Montenegro population during the whole study period of 30 years was 15.2/100,000 person-years. Slightly higher incidence rates were observed in male compared to female individuals, and the incidence increased with age, with the highest incidence in the 10–14 age group. If the model is observed as one without jointpoints, the annual percentage change (APC) for the total population is 3.1 (1.8–4.4); for male individuals, 3.8 (2.1–5.5); and for female individuals, 2.1 (0.6–3.5). In 2020, the first year of the coronavirus disease of 2019 (COVID-19) pandemic, in comparison to 2019, the incidence rate increased from 19.7/100,000 to 21.5/100,000, with the highest increase in the age group of 5–9 years. This is the first nationwide report on a 30-year period of T1D incidence trend in Montenegro. It suggests that T1D incidence among Montenegrin children is rising again and that there is a short-term influence of COVID-19 on new-onset T1D.
Introduction
Significant and unexplained variations in type 1 diabetes (T1D) incidence through the years were observed all around the world. The update on T1D incidence is crucial for unexceptional healthcare resource planning and monitoring of this disease, which is still unpreventable and concerning. Moreover, the incidence of T1D shows an increasing trend in Europe, and it sharply increased since 2019 (1).
North European countries (Finland, Sweden, Norway, the United Kingdom, and Ireland) are at the top of the list among countries with the highest incidence of T1D (27.5–52.2/100,000), but the incidence is also very high in the Italian region of Sardinia (45.0/100,000), which is located in the south-western part of Europe (1, 2).
According to the last census (2011), Montenegro is a south-eastern European country, with an area of 13,812 km2 and a population of 620,145, including 118,751 (19%) children younger than 15. Results of prior studies classified Montenegro as a country with a high incidence rate of T1D (18.5/100,000 for the period 2009–2013) (3, 4). However, the last report regarding the incidence of T1D was based on data from almost a decade ago, and analysis of more recent data is needed to gain insight into the current epidemiological situation regarding T1D in Montenegro.
The aim of this study was to give an update on the current incidence of pediatric T1D in Montenegro and to analyze incidence changes over time and how the exposure to different factors might have affected it, which should be useful for further projection of T1D prevalence.
Methods
The study included children younger than 15 years who were newly diagnosed with T1D during the period 1991–2020. The data source was the Diabetes Registry of Montenegro (established according to the EURODIAB Collaborative group propositions) and patients’ medical records at the Institute for Children’s Diseases, Clinical Center of Montenegro. The Institute for Children’s Diseases is the referent diabetes center for Montenegro, the only center where the diagnosis of T1D could be made and where insulin therapy is initially started and prescribed. Study protocol was formally approved by the Ethics Committee of Clinical Center of Montenegro (no. 03/01-24708). Second data source were records from the Institute of Public Health of Montenegro, which provided capture–recapture methodology (5). Children with other types of diabetes, such as type 2 diabetes or maturity-onset diabetes of the youth (MODY) were excluded from the study. The population denominator data were obtained from the 1991, 2003, and 2011 national census data of the Central Bureau of Statistics (Monstat). Due to long intervals between national censuses, the estimated numbers of habitants were used in order to obtain the number of habitants for each year in the period between 2000 and 2020. In the period from 1991 to 1999, no estimates of population were found, and due to the fact that during these years, there was a conflict in the region and subsequently high population migration, modeling of data was used to obtain estimates of the population in this period. For that purpose, the polynomial regression analysis was used to fit the data and impute the missing values.
Collected variables included gender, date of birth, and date of the onset of T1D. Three types of incidence rates, expressed as new cases per 100,000 persons, were calculated: age specific, age standardized, and crude. Age-specific rates were adjusted to three age groups (0–4, 5–9, and 10–14). Age-adjusted incidence rates were calculated using Segi’s World population (6).
The annual percentage change (APC), a number assumed as a constant percentage change of the previous year rate, was determined using jointpoint regression analysis. The joinpoint analysis was performed in Joinpoint Regression Program, v4.9.0.0, March 2021, Statistical Research and Applications Branch, National Cancer Institute.
Results
During the study period (1991–2020), there were a total of 582 children with newly diagnosed T1D, in which 317 were boys and 265 were girls. The average age at diagnosis was 8.4 ± 3.91 years. The mean annual incidence of T1D in the Montenegro population during the whole study period of 30 years was 15.2/100,000 person-years. The age- and sex-category-specific rates for the whole study period are shown in Table 1 and age-standardized incidence rate for 5-year period in Table 2.
Table 1 Number of cases, total person years, means annual incidence, age-specific incidence, and age-standardized incidence of T1D in Montenegro during the period 1991–2020.
Table 2 Age-standardized incidence rates of T1D in children aged 0–14 in Montenegro—5-year periods compared.
Slightly higher incidence rates were observed in male compared to female patients (Figure 1). The incidence increased with age, with the highest incidence in the 10–14 age group (Figure 2). The same trend is observed in the gender stratum (Table 1).
Figure 1 Trend of age-adjusted incidence rate (per 100,000), Montenegro, 1991–2020.
Figure 2 Trends of crude incidence rates of T1D in different age groups in (A) boys and (B) girls.
If the model is observed as one without jointpoints, the APC for the total population is 3.1 (1.8–4.4); for male individuals, 3.8 (2.1–5.5); and for female individuals, 2.1 (0.6–3.5). However, in both genders model, one significant joinpoint was obtained; for the period 1991–1995, APC is 40.96, while in the period 1995–2020, APC is 20.06. In female individuals, there is one significant joinpoint as well, and the APC for the period 1991–1995 is 36.76, while for the period 1995–2020, APC is 1.07. Every segment is shown separately in Figure 3.
Figure 3 Jointpoint regression analysis: trend of standardized incidence rates of T1D in different gender groups, in (A) total, (B) boys, and (C) girls.
In 2020, the first year of the COVID-19 pandemic, in comparison to 2019, the incidence rate increased from 19.7/100,000 to 21.5/100,000, with the highest increase in the age group of 5–9 years (Table 3), with similar variations among age and gender groups also reported at different time points during the past three decades.
Table 3 Crude incidence rate of T1D in Montenegro for the last 5 years, in different age groups.
Discussion
The results of this nationwide epidemiological study in 0–14-year-old children showed that Montenegro is a country with a high incidence rate of T1D (in the range of 10–19.9/100,000) (7, 8).
The previous report on the incidence of T1D in Montenegro has been published by Patterson et al., in their multicentric study, and our results point out that the incidence is higher since then (3). If we observe only the last 15-year period, the incidence of T1D in Montenegro can be classified as very high in male individuals younger than 15 (21.6–22.7/100,000). Knowing the data on T1D incidence trend, in the whole 0–14-year-old population and also in different age subgroups, is very important for the monitoring of the disease and for adequate healthcare resource planning and distribution.
In comparison to neighboring countries, T1D incidence in Montenegro is similar to Serbia (14.3/100,000 for the period 2007–2017), Slovenia (16.3/100,000 for the period 2009–2013), and Croatia (17.2/100,000 for the period 2004–2012), but it is significantly higher than in a Former Yugoslavian Republic of Macedonia (7.7/100,000 for the period 2009–2013) and Bosnia and Herzegovina–Tuzla region (6.9/100,000 for the period 1990–1998), which have higher rates of incidence increase in the later period than in previous countries (possibly due to prior underreporting of T1D) (3, 9–11).
During the 30 years of follow-up, the incidence increased by approximately 3.1% annually, but in the last years, the increase appears to be slowing down. The suggested slowing in the period 2004–2008 and cyclical 5-year periodicity in incidence pattern were not observed in our country (3).
Similarly across Europe, T1D is predominantly diagnosed in children 10–14 years old, but the average age at the onset of the disease is a bit lower (3, 12, 13). It could be due to the high childhood obesity rate or lower immunization coverage rate, which will be discussed in the following text. Opposite to other studies, we did not observe the highest incidence rate increase in boys younger than 5, but it is less marked in girls aged 0–4 years than in other age/sex subgroups (3, 14). In 2020, the highest incidence rate increase was among 5–9 years old.
Significant variations in T1D incidence through the years are still unexplained. Although, genetics, lifestyle, and socioeconomic factors play important roles in the development of type 1 diabetes, a majority of studies suggest environmental factors as crucial (15–17). The emphasis is on the decrease in infectious diseases frequency, increase in vaccination coverage rate, and changes in the food and supplements intake.
According to the accelerator hypothesis, childhood obesity significantly impacts the development and incidence of all types of diabetes, including T1D (18). In both obesity and type 1 diabetes, leptin, resistin, and β-cell autoimmunity are elevated, but it is not clear yet if obesity accelerates or causes type 1 diabetes (19). It is known that, in 2013, every fourth Montenegrin school-aged child was overweight, and the number of overweight boys was twice higher in comparison to girls (20). Since then, many inhabitants from the rural parts migrated to the urban parts of the country; a lot of people started a sedentary lifestyle with increased intake of high-calorie foods, which is expected to have led to even higher obesity rate and sustained increase in T1D incidence.
Like the rest of the world, Montenegro has been affected by the ongoing worldwide pandemic (COVID-19 pandemic) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus since its first case was confirmed on 17 March 2020. For more than 50 years, viruses are considered potential triggers for autoimmune diseases such as T1D (21, 22). Furthermore, some authors reported an increased incidence of new-onset T1D during the first year of the COVID-19 pandemic (23–25). SARS-CoV-2 tropism to pancreatic β cells is supposed to be due to their angiotensin-converting enzyme 2 (ACE2) receptors and neuropilin 1 (NRP1) receptors, and virus–receptor interactions lead to cell damage and impaired insulin secretion. Moreover, high blood glucose level “stimulates” replication of the virus and damage progress (26–28). Opposed to those findings and in line with our results, Mameli et al. have described the double wave occurrence, with the decrease in T1D incidence in the first wave of the COVID-19 pandemic, as also Kostopoulou reported (29, 30). It could be related to the fact that T1D is manifested a few months after a child’s contact with the trigger, in this case, the SARS-CoV-2 virus. On the other hand, if we observe a pandemic and strict lockdown in the first months as a stress, which could also be a trigger for T1D development, the incidence increase could be registered earlier (31). The highest increase in incidence rate during the first year of COVID-19 was observed in children older than 5 but younger than 10, which was also described as a finding in the Italian region of Calabria (13).
Hence, a similar peak in incidence rate to the one in the first year of the COVID pandemic was observed in 2016 (Table 3), which could be due to a significantly decreased rate of immunization with measles–mumps–rubella (MMR) vaccine among Montenegrin children that year (2015—whole country coverage of 93.5%, 98% in the capital city; 2016—whole country coverage of 86.4%, 73.0% in the capital city; 2017—whole country coverage of 92.2%, 97.7% in the capital city) (32–35). In the following years, the government introduced mandatory immunization certificates for children who want to stay in kindergarten, which improved the immunization coverage rate.
The strength of this study is its nationwide character and timeliness with a long observational period of 30 years supported by the completeness of the diabetes registry and high-quality data from the second source. The limitation of the present study is a lack of the exact number of inhabitants in the period 1991–1999, which we assumed and predicted using the mathematical mode (polynomial regression).
This is the first nationwide report on a 30-year period of T1D incidence trend in Montenegro. It suggests that T1D incidence among Montenegrin children is rising again, after a plateau, and that there is a short-term influence of COVID-19 on new-onset T1D. The highest increase in the first year of the COVID pandemic is registered in 5–9-year-olds.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Author contributions
MR, MS, and RV designed the research study. MR and NP gathered the data. IS conducted statistical analyses. MR and IS wrote the first draft of the manuscript. All authors contributed to study design and revised and approved the final version of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
T1D, type 1 diabetes; EURODIAB, a collaboration of European Childhood Diabetes Registers; MODY, maturity onset diabetes of youth; APC, annual percentage change; COVID-19, coronavirus disease of 2019.
References
1. IDF Diabetes Atlas. Idf diabetes atlas Vol. 2021. Brussels: International Diabetes Federation © International Diabetes Federation (2021).
2. Songini M, Mannu C, Targhetta C, Bruno G. Type 1 diabetes in Sardinia: facts and hypotheses in the context of worldwide epidemiological data. Acta Diabetol (2017) 54(1):9–17. doi: 10.1007/s00592-016-0909-2
3. Patterson CC, Harjutsalo V, Rosenbauer J, Neu A, Cinek O, Skrivarhaug T, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia (2019) 62(3):408–17. doi: 10.1007/s00125-018-4763-3
4. Samardžić M, Martinović M, Nedović-Vuković M, Popović-Samardžić M. Recent incidence of type 1 diabetes mellitus in Montenegro: A shift toward younger age At disease onset. Acta Clin Croat (2016) 55(1):63–8. doi: 10.20471/acc.2016.55.01.10
5. LaPorte RE, McCarty D, Bruno G, Tajima N, Baba S. Counting diabetes in the next millennium. application of capture-recapture technology. Diabetes Care (1993) 16(2):528–34. doi: 10.2337/diacare.16.2.528
6. Segi M. Cancer mortality for selected sites in 24 countries (1950-57). Sendai: Tohoku University School of Public Health (1960).
7. Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect (2020) 10(2):98–115. doi: 10.34172/hpp.2020.18
8. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. diabetes mondiale (DiaMond) project group. Diabetes Care (2000) 23(10):1516–26. doi: 10.2337/diacare.23.10.1516
9. Vukovic R, Jesic MD, Vorgucin I, Stankovic S, Folic N, Milenkovic T, et al. First report on the nationwide incidence of type 1 diabetes and ketoacidosis at onset in children in Serbia: a multicenter study. Eur J Pediatr (2018) 177(8):1155–62. doi: 10.1007/s00431-018-3172-4
10. Rojnic Putarek N, Ille J, Spehar Uroic A, Skrabic V, Stipancic G, Krnic N, et al. Incidence of type 1 diabetes mellitus in 0 to 14-yr-old children in Croatia–2004 to 2012 study. Pediatr Diabetes (2015) 16(6):448–53. doi: 10.1111/pedi.12197
11. Bratina NU, Tahirović H, Battelino T, Krzisnik C. Incidence of childhood-onset type I diabetes in Slovenia and the Tulza region (Bosnia and Herzegovina) in the period 1990-1998. Diabetologia (2001) 44:B27–31. doi: 10.1007/PL00002949
12. Maahs DM, West NA, Lawrence JM, Mayer-Davis EJ. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am (2010) 39(3):481–97. doi: 10.1016/j.ecl.2010.05.011
13. Passanisi S, Salzano G, Aloe M, Bombaci B, Citriniti F, De Berardinis F, et al. Increasing trend of type 1 diabetes incidence in the pediatric population of the calabria region in 2019-2021. Ital J Pediatr (2022) 48(1):66. doi: 10.1186/s13052-022-01264-z
14. Chobot A, Polanska J, Brandt A, Deja G, Glowinska-Olszewska B, Pilecki O, et al. Updated 24-year trend of type 1 diabetes incidence in children in Poland reveals a sinusoidal pattern and sustained increase. Diabetes Med (2017) 34(9):1252–8. doi: 10.1111/dme.13345
15. Lukács K, Pánczél P, Hosszúfalusi N. [Environmental factors and epidemiology of childhood type 1 diabetes]. Orv Hetil (2021) 162(1):13–22 .doi: 10.1556/650.2021.31952
16. Rewers M, Ludvigsson J. Environmental risk factors for type 1 diabetes. Lancet (2016) 387(10035):2340–8. doi: 10.1016/S0140-6736(16)30507-4
17. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet (2009) 373(9680):2027–33. doi: 10.1016/S0140-6736(09)60568-7
18. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia (2001) 44(7):914–22. doi: 10.1007/s001250100548
19. Tsigalou C, Vallianou N, Dalamaga M. Autoantibody production in obesity: Is there evidence for a link between obesity and autoimmunity? Curr Obes Rep (2020) 9(3):245–54. doi: 10.1007/s13679-020-00397-8
20. Martinovic M, Belojevic G, Evans GW, Lausevic D, Asanin B, Samardzic M, et al. Prevalence of and contributing factors for overweight and obesity among Montenegrin schoolchildren. Eur J Public Health (2015) 25(5):833–9. doi: 10.1093/eurpub/ckv071
21. Gamble DR, Kinsley ML, FitzGerald MG, Bolton R, Taylor KW. Viral antibodies in diabetes mellitus. Br Med J (1969) 3(5671):627–30. doi: 10.1136/bmj.3.5671.627
22. Isaacs SR, Foskett DB, Maxwell AJ, Ward EJ, Faulkner CL, Luo JYX, et al. Viruses and type 1 diabetes: From enteroviruses to the virome. Microorganisms (2021) 9(7):1–26. doi: 10.3390/microorganisms9071519
23. Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-onset type 1 diabetes in children during COVID-19: Multicenter regional findings in the U.K. Diabetes Care (2020) 43(11):e170–1. doi: 10.2337/dc20-1551
24. Caruso P, Longo M, Esposito K, Maiorino MI. Type 1 diabetes triggered by covid-19 pandemic: A potential outbreak? Diabetes Res Clin Pract (2020) 164:108219. doi: 10.1016/j.diabres.2020.108219
25. Rahmati M, Keshvari M, Mirnasuri S, Yon DK, Lee SW, Il Shin J, et al. The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis. J Med Virol (2022) 1–16. doi: 10.1002/jmv.27996
26. Lim S, Bae JH, Kwon H-S, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol (2021) 17(1):11–30. doi: 10.1038/s41574-020-00435-4
27. Pranata R, Henrina J, Raffaello WM, Lawrensia S, Huang I. Diabetes and COVID-19: The past, the present, and the future. Metabolism (2021) 121:154814. doi: 10.1016/j.metabol.2021.154814
28. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science (2020) 370(6518):856–60. doi: 10.1126/science.abd2985
29. Mameli C, Scaramuzza A, Macedoni M, Marano G, Frontino G, Luconi E, et al. Type 1 diabetes onset in Lombardy region, Italy, during the COVID-19 pandemic: The double-wave occurrence. EClinicalMedicine (2021) 39:101067. doi: 10.1016/j.eclinm.2021.101067
30. Kostopoulou E, Eliopoulou MI, Rojas Gil AP, Chrysis D. Impact of COVID-19 on new-onset type 1 diabetes mellitus - a one-year prospective study. Eur Rev Med Pharmacol Sci (2021) 25(19):5928–35. doi: 10.26355/eurrev_202110_26869
31. Tittel SR, Rosenbauer J, Kamrath C, Ziegler J, Reschke F, Hammersen J, et al. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany? Diabetes Care (2020) 43(11):e172–3. doi: 10.2337/dc20-1633
32. Health statistical yearbook 2015 of Montenegro. Podgorica: Institute for Public Health of Montenegro (2017).
33. Health statistical yearbook 2016 of Montenegro. Podgorica: Institute for Public Health of Montenegro (2018).
34. Health statistical yearbook 2017 of Montenegro. Podgorica, Montenegro: Institute for Public Health of Montenegro (2019).
Keywords: diabetes mellitus, T1D, incidence, COVID19, Montenegro (Crna Gora)
Citation: Raicevic M, Samardzic M, Soldatovic I, Curovic Popovic N and Vukovic R (2022) Trends in nationwide incidence of pediatric type 1 diabetes in Montenegro during the last 30 years. Front. Endocrinol. 13:991533. doi: 10.3389/fendo.2022.991533
Received: 11 July 2022; Accepted: 18 August 2022;
Published: 06 September 2022.
Edited by:
Willem Staels, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), BelgiumReviewed by:
Natasa Bratina, University Medical Centre Ljubljana, SloveniaStefano Passanisi, University of Messina, Italy
Copyright © 2022 Raicevic, Samardzic, Soldatovic, Curovic Popovic and Vukovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maja Raicevic, bWFqYXJhaWNldmljODlAZ21haWwuY29t
†ORCID: Maja Raicevic, orcid.org/0000-0001-7007-0571